GLP-1 receptor agonists linked to reduced Parkinson's disease incidence in large retrospective case-control study

There are currently no disease-modifying treatments for Parkinson's disease (PD), a progressive neurodegenerative disorder characterized by dopaminergic neuron loss and α-synuclein aggregation. Existing therapies only offer symptomatic relief, highlighting an urgent need for interventions that can slow or halt disease progression. Glucagon-like peptide-1 receptor (GLP-1R) agonists, known for their neuroprotective effects in metabolic diseases, are emerging as potential therapeutic candidates for neurodegenerative conditions like PD, warranting further investigation into their long-term impact.

Researchers conducted a retrospective case-control study using data from the Clinical Practice Research Datalink. They identified 37,910 individuals diagnosed with Parkinson's disease and matched them by age, sex, and general practice to 113,730 controls. Biometric measures and prescription histories were analyzed across two pre-diagnostic windows: 5-10 years and 10-20 years before diagnosis. Logistic regression models were employed to assess associations between biomarkers, medication exposure, and PD incidence, and a composite risk score was developed and evaluated using receiver operating characteristic analysis.

Individuals who developed Parkinson's disease exhibited significant deviations in established vascular, metabolic, and inflammatory markers years before diagnosis, including elevated systolic blood pressure, serum urea, and creatinine. The combined risk model demonstrated moderate predictive accuracy, achieving an area under the curve (AUC) of 0.73. Previously reported contrasting associations of salbutamol and propranolol with PD incidence were confirmed. Hormonal therapies and triptan medications were associated with lower disease incidence, but this finding was potentially confounded as these medications were more frequently prescribed to individuals with more favorable biometric risk profiles.

In contrast, glucagon-like peptide-1 receptor agonists were prescribed to individuals with higher underlying risk yet were associated with reduced disease incidence, suggesting a robust protective effect.